{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:23:03Z","timestamp":1747207383947,"version":"3.40.5"},"reference-count":63,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2020,5,20]]},"abstract":"<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The high cost of orphan drugs limits their access by many patients, especially in\nlow- and middle-income countries. Many orphan drugs are off-patent without alternative generic or biosimilar\nversions available. Production of these drugs at the point-of-care, when feasible, could be a\ncost-effective alternative.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The financial feasibility of this approach was estimated by setting up a small-scale production\nof recombinant human acid alpha-glucosidase (rhGAA). The commercial version of rhGAA is\nMyozyme\u2122, and Lumizyme\u2122 in the United States, which is used to treat Pompe disease. The rhGAA\nwas produced in CHO-K1 mammalian cells and purified using multiple purification steps to obtain a\nprotein profile comparable to Myozyme\u2122.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The established small-scale production of rhGAA was used to obtain a realistic cost estimation\nfor the magistral production of this biological drug. The treatment cost of rhGAA using bedside\nproduction was estimated at $3,484\/gram, which is 71% lower than the commercial price of Myozyme\n\u2122.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This study shows that bedside production might be a cost-effective approach to increase\nthe access of patients to particular life-saving drugs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201021666200217113049","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T11:58:36Z","timestamp":1581940716000},"page":"467-479","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Feasibility Study for Bedside Production of Recombinant Human Acid \u03b1-Glucosidase: Technical and Financial Considerations"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1301-5669","authenticated-orcid":true,"given":"Mohammed H.","family":"Aldosari","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1377-9434","authenticated-orcid":true,"given":"Marcel","family":"den Hartog","sequence":"additional","affiliation":[{"name":"Bioceros B.V., Utrecht, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4614-2146","authenticated-orcid":true,"given":"Hubertina","family":"Ganizada","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6112-0717","authenticated-orcid":true,"given":"Martijn J.W.","family":"Evers","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6745-2015","authenticated-orcid":true,"given":"Enrico","family":"Mastrobattista","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8503-3965","authenticated-orcid":true,"given":"Huub","family":"Schellekens","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","author":"Field M.J.","year":"2010","unstructured":"Field M.J.; Boat T.F.;  Profile of Rare Diseases 2010","journal-title":"Profile of Rare Diseases"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5582\/irdr.3.1","volume":"3","author":"Hall A.K.","year":"2014","unstructured":"Hall A.K.; Carlson M.R.; The current status of orphan drug development in Europe and the US. Intractable Rare Dis Res 2014,3(1),1-7","journal-title":"Intractable Rare Dis Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13167-016-0074-2","volume":"7","author":"G\u00fclbakan B.","year":"2016","unstructured":"G\u00fclbakan B.; \u00d6zg\u00fcl R.K.; Y\u00fczba\u015f\u0131o\u011flu A.; Kohl M.; Deigner H-P.; \u00d6zg\u00fc\u00e7 M.; Discovery of biomarkers in rare diseases: innovative approaches by predictive and personalized medicine. EPMA J 2016,7(1),24","journal-title":"EPMA J"},{"key":"ref=4","first-page":"128","volume":"5","author":"Puiu M.","year":"2010","unstructured":"Puiu M.; Dan D.; Rare diseases, from European resolutions and recommendations to actual measures and strategies. Maedica (Buchar) 2010,5(2),128-131","journal-title":"Maedica (Buchar)"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/s41431-017-0008-z","volume":"25","author":"Lochm\u00fcller H.","year":"2017","unstructured":"Lochm\u00fcller H.; Torrent I Farnell J.; Le Cam Y.; Jonker A.H.; Lau L.P.; Baynam G.; Kaufmann P.; Dawkins H.J.; Lasko P.; Austin C.P.; Boycott K.M.; The International Rare Diseases Research Consortium: Policies and Guidelines to maximize impact. Eur J Hum Genet 2017,25(12),1293-1302","journal-title":"Eur J Hum Genet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13023-017-0617-1","volume":"12","author":"Giannuzzi V.","year":"2017","unstructured":"Giannuzzi V.; Conte R.; Landi A.; Ottomano S.A.; Bonifazi D.; Baiardi P.; Bonifazi F.; Ceci A.; Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen. Orphanet J Rare Dis 2017,12(1),64","journal-title":"Orphanet J Rare Dis"},{"key":"ref=7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140002","volume":"10","author":"Gammie T.","year":"2015","unstructured":"Gammie T.; Lu C.Y.; Babar Z.U-D.; Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. PLoS One 2015,10(10)","journal-title":"PLoS One"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.healthpol.2017.09.005","volume":"121","author":"Degtiar I.","year":"2017","unstructured":"Degtiar I.; A review of international coverage and pricing strategies for personalized medicine and orphan drugs. Health Policy 2017,121(12),1240-1248","journal-title":"Health Policy"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jval.2018.01.007","volume":"21","author":"Deti\u010dek A.","year":"2018","unstructured":"Deti\u010dek A.; Locatelli I.; Kos M.; Patient Access to Medicines for Rare Diseases in European Countries. Value Health 2018,21(5),553-560","journal-title":"Value Health"},{"year":"2018","key":"ref=10","unstructured":"Orphan Drug Report 2018; EvaluatePharma: London, United Kingdom, 2018"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.csbj.2016.06.007","volume":"14","author":"Jacquemart R.","year":"2016","unstructured":"Jacquemart R.; Vandersluis M.; Zhao M.; Sukhija K.; Sidhu N.; Stout J.; A single-use strategy to enable manufacturing of affordable biologics. Comput Struct Biotechnol J 2016,14,309-318","journal-title":"Comput Struct Biotechnol J"},{"key":"ref=12","unstructured":"The Next Generation of Biotech Manufacturing.,"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nbt.3888","volume":"35","author":"Schellekens H.","year":"2017","unstructured":"Schellekens H.; Aldosari M.; Talsma H.; Mastrobattista E.; Making individualized drugs a reality. Nat Biotechnol 2017,35(6),507-513","journal-title":"Nat Biotechnol"},{"journal-title":"Quality and Safety Standards in Pharmaceutical Practices and Pharmaceutical Care: Resolutions","key":"ref=14","unstructured":"European Directorate for the Quality of Medicines Quality and Safety Standards in Pharmaceutical Practices and Pharmaceutical Care: Resolutions  [accessed Jun 1, 2018]."},{"key":"ref=15","first-page":"25","year":"2018","unstructured":"Orphan Drugs in the United States 2018,25","journal-title":"Orphan Drugs in the United States"},{"key":"ref=16","unstructured":"Personalised Medicine Produced in a \u201cBionexpresso\u201d."},{"key":"ref=17","unstructured":"FDA approves first treatment for Pompe disease."},{"key":"ref=18","unstructured":"Myozyme.,"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","volume":"8","author":"Kishnani P.S.","year":"2006","unstructured":"Kishnani P.S.; Steiner R.D.; Bali D.; Berger K.; Byrne B.J.; Case L.E.; Crowley J.F.; Downs S.; Howell R.R.; Kravitz R.M.; Mackey J.; Marsden D.; Martins A.M.; Millington D.S.; Nicolino M.; O\u2019Grady G.; Patterson M.C.; Rapoport D.M.; Slonim A.; Spencer C.T.; Tifft C.J.; Watson M.S.; Pompe disease diagnosis and management guideline. Genet Med 2006,8(5),267-288","journal-title":"Genet Med"},{"year":"1993","author":"Leslie N.","key":"ref=20","unstructured":"Leslie N.; Tinkle B.T.;  Glycogen storage disease type II Pompe disease. Gene Reviews; Pagon, R.A.; Adam, M.P.; Ardinger, H.H.; Wallace, S.E.; Amemiya, A.; Bean, L.J.; Bird, T.D., Eds.; University of Washington, Seattle: Seattle, WA 1993"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.jpeds.2004.01.053","volume":"144","author":"Kishnani P.S.","year":"2004","unstructured":"Kishnani P.S.; Howell R.R.; Pompe disease in infants and children. J Pediatr 2004,144(5)(Suppl.),S35-S43","journal-title":"J Pediatr"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1042\/bj2720485","volume":"272","author":"Hoefsloot L.H.","year":"1990","unstructured":"Hoefsloot L.H.; Willemsen R.; Kroos M.A.; Hoogeveen-Westerveld M.; Hermans M.M.; Van der Ploeg A.T.; Oostra B.A.; Reuser A.J.; Expression and routeing of human lysosomal alpha-glucosidase in transiently transfected mammalian cells. Biochem J 1990,272(2),485-492","journal-title":"Biochem J"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"6780","DOI":"10.1074\/jbc.M404008200","volume":"280","author":"Moreland R.J.","year":"2005","unstructured":"Moreland R.J.; Jin X.; Zhang X.K.; Decker R.W.; Albee K.L.; Lee K.L.; Cauthron R.D.; Brewer K.; Edmunds T.; Canfield W.M.; Lysosomal acid \u03b1-glucosidase consists of four different peptides processed from a single chain precursor. J Biol Chem 2005,280(8),6780-6791","journal-title":"J Biol Chem"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","volume":"288","author":"Maga J.A.","year":"2013","unstructured":"Maga J.A.; Zhou J.; Kambampati R.; Peng S.; Wang X.; Bohnsack R.N.; Thomm A.; Golata S.; Tom P.; Dahms N.M.; Byrne B.J.; LeBowitz J.H.; Glycosylation-independent lysosomal targeting of acid \u03b1-glucosidase enhances muscle glycogen clearance in pompe mice. J Biol Chem 2013,288(3),1428-1438","journal-title":"J Biol Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ymgme.2008.04.009","volume":"94","author":"McVie-Wylie A.J.","year":"2008","unstructured":"McVie-Wylie A.J.; Lee K.L.; Qiu H.; Jin X.; Do H.; Gotschall R.; Thurberg B.L.; Rogers C.; Raben N.; O\u2019Callaghan M.; Canfield W.; Andrews L.; McPherson J.M.; Mattaliano R.J.; Biochemical and pharmacological characterization of different recombinant acid \u03b1-glucosidase preparations evaluated for the treatment of Pompe disease. Mol Genet Metab 2008,94(4),448-455","journal-title":"Mol Genet Metab"},{"key":"ref=26","unstructured":"Myozyme Becomes Lumizyme After Biologics Scale-up, Myozyme-becomes-Lumizyme-after-biologics-scale-up"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nbt0809-685a","volume":"27","author":"Ratner M.","year":"2009","unstructured":"Ratner M.; Genzyme\u2019s lumizyme clears bioequivalence hurdles. Nat Biotechnol 2009,27,685","journal-title":"Nat Biotechnol"},{"key":"ref=28","unstructured":"Genzyme. Genzyme Receives Label Expansion for Lumizyme (Alglucosidase Alfa) in the United States for the Treatment of Pompe disease,"},{"key":"ref=29","unstructured":"FDA expands approval of drug to treat Pompe disease,"},{"key":"ref=30","unstructured":"Forbes. The World\u2019s Most Expensive Drugs,"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1750-1172-9-75","volume":"9","author":"Kanters T.A.","year":"2014","unstructured":"Kanters T.A.; Hoogenboom-Plug I.; Rutten-Van M\u00f6lken M.P.; Redekop W.K.; van der Ploeg A.T.; Hakkaart L.; Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease. Orphanet J Rare Dis 2014,9(1),75","journal-title":"Orphanet J Rare Dis"},{"journal-title":"Treatment of Pompe\u2019s disease","author":"Patents G.","key":"ref=32","unstructured":"Patents G.;  Treatment of Pompe\u2019s disease"},{"key":"ref=33","first-page":"469","volume":"6","author":"Blackstone E.A.","year":"2013","unstructured":"Blackstone E.A.; Joseph P.F.; The economics of biosimilars. Am Health Drug Benefits 2013,6(8),469-478","journal-title":"Am Health Drug Benefits"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"8115","DOI":"10.1021\/acs.analchem.5b00870","volume":"87","author":"Geuijen K.P.M.","year":"2015","unstructured":"Geuijen K.P.M.; Halim L.A.; Schellekens H.; Schasfoort R.B.; Wijffels R.H.; Eppink M.H.; Label-free glycoprofiling with multiplex surface plasmon resonance: a tool to quantify sialylation of erythropoietin. Anal Chem 2015,87(16),8115-8122","journal-title":"Anal Chem"},{"key":"ref=35","author":"Freeze H.H.","year":"1995","unstructured":"Freeze H.H.; Lectin affinity chromatography. Curr Protocols Protein Sci, (1), 9.1.1-9.1.9.1995","journal-title":"Curr Protocols Protein Sci,"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"480","DOI":"10.4161\/mabs.2.5.12645","volume":"2","author":"Liu H.F.","year":"2010","unstructured":"Liu H.F.; Ma J.; Winter C.; Bayer R.; Recovery and purification process development for monoclonal antibody production. MAbs 2010,2(5),480-499","journal-title":"MAbs"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.chroma.2007.03.126","volume":"1154","author":"Soper A.S.","year":"2007","unstructured":"Soper A.S.; Aird S.D.; Elution of tightly bound solutes from concanavalin A Sepharose. Factors affecting the desorption of cottonmouth venom glycoproteins. J Chromatogr A 2007,1154(1-2),308-318","journal-title":"J Chromatogr A"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0021-9673(01)01275-4","volume":"933","author":"DePhillips P.","year":"2001","unstructured":"DePhillips P.; Lenhoff A.M.; Determinants of protein retention characteristics on cation-exchange adsorbents. J Chromatogr A 2001,933(1-2),57-72","journal-title":"J Chromatogr A"},{"key":"ref=39","author":"Janson J-C.","year":"2012","unstructured":"Janson J-C.;  Protein Purification: Principles, High Resolution Methods, and Applications 2012","journal-title":"Protein Purification: Principles, High Resolution Methods, and Applications"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/glycob\/cws058","volume":"22","author":"Castonguay A.C.","year":"2012","unstructured":"Castonguay A.C.; Lasanajak Y.; Song X.; Olson L.J.; Cummings R.D.; Smith D.F.; Dahms N.M.; The glycan-binding properties of the cation-independent mannose 6-phosphate receptor are evolutionary conserved in vertebrates. Glycobiology 2012,22(7),983-996","journal-title":"Glycobiology"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/glycob\/cwv001","volume":"25","author":"Olson L.J.","year":"2015","unstructured":"Olson L.J.; Castonguay A.C.; Lasanajak Y.; Peterson F.C.; Cummings R.D.; Smith D.F.; Dahms N.M.; Identification of a fourth mannose 6-phosphate binding site in the cation-independent mannose 6-phosphate receptor. Glycobiology 2015,25(6),591-606","journal-title":"Glycobiology"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1755-8417-1-6","volume":"1","author":"Cardone M.","year":"2008","unstructured":"Cardone M.; Porto C.; Tarallo A.; Vicinanza M.; Rossi B.; Polishchuk E.; Donaudy F.; Andria G.; De Matteis M.A.; Parenti G.; Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts. PathoGenetics 2008,1(1),6","journal-title":"PathoGenetics"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2307\/1906860","volume":"8","author":"Preinreich G.A.D.","year":"1940","unstructured":"Preinreich G.A.D.; The economic life of industrial equipment. Econometrica 1940,8(1),12-44","journal-title":"Econometrica"},{"key":"ref=44","first-page":"147","volume":"10","author":"Wiebe M.E.","year":"1990","unstructured":"Wiebe M.E.; May L.H.; Cell banking. Bioprocess Technol 1990,10,147-160","journal-title":"Bioprocess Technol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11584230-000000000-00000","volume":"29","author":"Hoyle M.","year":"2011","unstructured":"Hoyle M.; Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis. Pharmacoeconomics 2011,29(1),1-15","journal-title":"Pharmacoeconomics"},{"key":"ref=46","unstructured":"GE Healthcare Life Sciences. Single-use Ready to Process Wave Cellbag Bioreactors,"},{"key":"ref=47","unstructured":"GE Healthcare Life Sciences. HyClone CDM4CHO Cell Culture Media,"},{"key":"ref=48","unstructured":"GE Healthcare Life Sciences. Disposable Cellbag Bioreactors for Wave Bioreactor Systems,"},{"journal-title":"Characteristics of CHO-K1 cell line","author":"Sammlung von Mikroorganismen D.","key":"ref=49","unstructured":"Sammlung von Mikroorganismen D.; Zellkulturen G.H.;  Characteristics of CHO-K1 cell line"},{"key":"ref=50","unstructured":"Repligen. KrosFlo KML,"},{"key":"ref=51","unstructured":"GE Healthcare Life Sciences. Permeate Volume and Process Time calculator for Cross-flow Filtration,"},{"key":"ref=52","unstructured":"Repligen. MIDIKROS 65CM 10K MPES,"},{"key":"ref=53","unstructured":"GE Healthcare Life Sciences. \u00c4KTA Ready Single-Use System,"},{"key":"ref=54","unstructured":"GE Healthcare Life Sciences. Con A Sepharose 4B,"},{"key":"ref=55","unstructured":"GE Healthcare Life Sciences. DEAE Sepharose Fast Flow Anion\tExchange Chromatography Resin,"},{"key":"ref=56","first-page":"613","volume":"43","author":"Van Hove J.L.","year":"1997","unstructured":"Van Hove J.L.; Yang H.W.; Oliver L.M.; Pennybacker M.F.; Chen Y.T.; Purification of recombinant human precursor acid alpha-glucosidase. Biochem Mol Biol Int 1997,43(3),613-623","journal-title":"Biochem Mol Biol Int"},{"journal-title":"M1 Filling Station","key":"ref=57","unstructured":"Aseptic Technologies.  M1 Filling Station"},{"key":"ref=58","unstructured":"Type A2 Biosafety Cabinets,"},{"journal-title":"Average Pharmacist Salary","key":"ref=59","unstructured":"Total Jobs.  Average Pharmacist Salary"},{"key":"ref=60","unstructured":"GE Healthcare Life Sciences. Ready to Process Wave 25 Rocker,"},{"key":"ref=61","unstructured":"Liquid Chromatography (HPLC"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cts.12500","volume":"11","author":"Austin C.P.","year":"2018","unstructured":"Austin C.P.; Cutillo C.M.; Lau L.P.L.; Jonker A.H.; Rath A.; Julkowska D.; Thomson D.; Terry S.F.; de Montleau B.; Ardig\u00f2 D.; Hivert V.; Boycott K.M.; Baynam G.; Kaufmann P.; Taruscio D.; Lochm\u00fcller H.; Suematsu M.; Incerti C.; Draghia-Akli R.; Norstedt I.; Wang L.; Dawkins H.J.S.; Future of rare diseases research 2017-2027: An IRDiRC perspective. Clin Transl Sci 2018,11(1),21-27","journal-title":"Clin Transl Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1517\/21678707.2013.819289","volume":"1","author":"Cohen J.","year":"2013","unstructured":"Cohen J.; Milne C-P.; Is the increasing cost of treating rare diseases sustainable? Expert Opin Orphan Drugs 2013,1(8),581-583","journal-title":"Expert Opin Orphan Drugs"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/179428","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T09:13:17Z","timestamp":1593681197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/179428\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,5,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201021666200217113049","relation":{},"ISSN":["1389-2010"],"issn-type":[{"type":"print","value":"1389-2010"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}